Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
Would you perform salpingo-oophorectomy for a premenopausal woman with an estrogen receptor-negative, uterine-confined embryonal rhabdomyosarcoma?
Related Questions
How would you manage bulky cervical adenocarcinoma that incompletely responded to primary chemoradiation?
Would you use a GI regimen (FOLFOX) or a GYN regimen (Carboplatin/Paclitaxel +/- immuno) for a 71yo women with ascites, a large pelvic mass arising from the uterus (on CT), and peritoneal implants that are CDX2 positive, PAX 8 / WT-1 negative, p53 wild type, intestinal type?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
For a patient who has vaginal cuff recurrence <6 months after adjuvant pelvic radiotherapy to a dose of 45 Gy, how would you approach management?
How do you approach radiation treatment of extramammary Paget's disease of vulva, diffusely involving the urothelium and the periurethral glands?
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
How would you evaluate the role for adjuvant radiation in a very young female (20s) with a localized vulvar SCC, HPV independent, status post hemivulvectomy?
